pioglitazone has been researched along with d-alpha tocopherol in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.57) | 18.2507 |
| 2000's | 7 (12.50) | 29.6817 |
| 2010's | 37 (66.07) | 24.3611 |
| 2020's | 10 (17.86) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Inoue, I; Katayama, S; Komoda, T; Miyazaki, T; Negishi, K; Sonoda, M; Takahashi, K | 1 |
| Ishizawa, M; Ishizuka, T; Itaya, S; Kajita, K; Kanoh, Y; Kimura, M; Miura, A; Muto, N; Wada, H; Yasuda, K | 1 |
| Hisatome, I; Ogino, K; Shigemasa, C; Shimoyama, M; Uchida, K | 1 |
| Arima, S; Ikeda, Y; Ito, S; Kudo, M; Sato, K; Sugawara, A; Takeuchi, K; Taniyama, Y; Uruno, A | 1 |
| Dobrian, AD; Khraibi, AA; Prewitt, RL; Schriver, SD | 1 |
| Adams, LA; Angulo, P | 1 |
| Clore, J; Contos, MJ; Luketic, VA; Mills, AS; Mofrad, PS; Sanyal, AJ; Sargeant, C; Shiffman, ML; Sterling, RK; Stravitz, RT | 1 |
| Chalasani, NP; Hoofnagle, J; Kleiner, DE; Kowdley, KV; Robuck, PR; Sanyal, AJ; Tonascia, J; Unalp, A | 1 |
| Dhawan, A; Dziechciarz, P; Horvath, A; Socha, P; Szajewska, H; Vajro, P | 1 |
| Bass, NM; Brunt, EM; Chalasani, N; Clark, J; Diehl, AM; Hoofnagle, JH; Kleiner, DE; Kowdley, KV; Lavine, JE; McCullough, A; Neuschwander-Tetri, BA; Robuck, PR; Sanyal, AJ; Tonascia, J; Unalp, A; Van Natta, M | 1 |
| Devi, K; Khanam, S; Rabbani, SI | 1 |
| Adams, LA; Smith, BW | 1 |
| Grønbæk, H; Heebøll, S; Kazankov, K; Poulsen, MK; Vilstrup, H | 1 |
| Bass, NM; Bell, LN; Brunt, EM; Chalasani, N; Chalasani, S; Diehl, AM; Fullenkamp, AM; Kowdley, KV; McCullough, AJ; Muralidharan, S; Neuschwander-Tetri, BA; Sanyal, AJ; Unalp-Arida, A; Wang, J; Wilson, LA | 1 |
| Craig, JC; George, J; Mahady, SE; Wong, G | 1 |
| Pacana, T; Sanyal, AJ | 1 |
| Bril, F; Cusi, K; Lomonaco, R; Sunny, NE | 1 |
| Clark, JM; Hoofnagle, JH; Kleiner, DE; Kowdley, KV; Loomba, R; Neuschwander-Tetri, BA; Sanyal, AJ; Tonascia, J; Van Natta, ML | 1 |
| Loomba, R; Pearlman, M | 1 |
| Chalasani, N; Corey, KE; Cummings, OW; Vuppalanchi, R; Wilson, LA | 1 |
| Anstee, QM; Day, CP; Hardy, T | 1 |
| Rinella, ME | 1 |
| Allen, AM; Khera, R; Loomba, R; Murad, MH; Singh, S | 1 |
| Ahmed, A; Harrison, SA; Wong, RJ | 1 |
| Corey, KE; Rinella, ME | 1 |
| Dufour, JF; Perazzo, H | 1 |
| Oseini, AM; Sanyal, AJ | 1 |
| Banini, BA; Sanyal, AJ | 2 |
| Newsome, PN; Townsend, SA | 1 |
| Mao, YM; Tang, JT | 1 |
| Gao, CQ; Jin, CL; Li, HC; Wang, Q; Wang, XQ; Xu, YL; Yan, HC; Zhang, ZM | 1 |
| Grønbæk, H; Heebøll, S; Vilstrup, H | 1 |
| Kumar, RB; Mathews, SE; Shukla, AP | 1 |
| Honda, Y; Imajo, K; Kessoku, T; Kobayashi, T; Nakajima, A; Ogawa, Y; Saito, S; Yoneda, M | 1 |
| Chaiyakunapruk, N; Chongmelaxme, B; Dilokthornsakul, P; Phisalprapa, P; Sawangjit, R | 1 |
| Brunt, EM; Kleiner, DE; Neuschwander-Tetri, BA; Sanyal, AJ; Wilson, LA | 1 |
| Cheung, A; Figueredo, C; Rinella, ME | 1 |
| Altinbas, A; Chalasani, N; Chung, RT; Corey, KE; Kleiner, DE; Krauss, RM; Wilson, LA; Yates, KP | 1 |
| Anushiravani, A; Haddadi, N; Mohammadkarimi, V; Pourfarmanbar, M | 1 |
| Brunner, KT; Henneberg, CJ; Long, MT; Wilechansky, RM | 1 |
| Byrne, CD; Jennison, E; Patel, J; Scorletti, E | 1 |
| Bottomley, J; Jiandani, NR; Oliver, L; Perry, R; Povsic, M | 1 |
| Al-Hamoudi, WK; Al-Judaibi, B; Al-Osaimi, A; Alswat, KA; Alturaify, N; Elsiesy, HA; Fallatah, HI; Qutub, AN | 1 |
| Biernacki, DM; Bril, F; Cusi, K; Hecht, J; Kalavalapalli, S; Lai, J; Lomonaco, R; Orsak, BK; Subbarayan, SK; Suman, A; Tio, F | 1 |
| Nakajima, A; Ogawa, Y; Okanoue, T; Sumida, Y; Yoneda, M | 1 |
| Chi, X; DeBoer, MD; Gurka, MJ; Mack, JA | 1 |
| Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A | 1 |
| Chaikuad, A; Gellrich, L; Heering, J; Kluge, S; Knapp, S; Lorkowski, S; Merk, D; Schubert-Zsilavecz, M; Werz, O; Willems, S | 1 |
| Barnard, A; Dave, S; Loomba, R; Majzoub, AM; Munaganuru, N; Murad, MH; Nayfeh, T; Singh, S | 1 |
| Chen, B; Gao, F; Gu, Y; Liu, P; Liu, Q; Liu, W; Wu, P; Xiao, Y; Xie, W | 1 |
| Aveyard, P; Cobbold, JF; Heath, L; Koutoukidis, DA; Tomlinson, JW | 1 |
| Alexander, L; Behling, C; Biegel, H; Chalasani, N; Dasarathy, S; Diehl, AM; Hameed, B; Jia, Y; Karpen, SJ; Kleiner, DE; Kowdley, KV; Lavine, JE; Loomba, R; Neuschwander-Tetri, BA; Ostroff, R; Sanyal, AJ; Tonascia, J; Williams, J; Williams, SA; Yates, KP | 1 |
| Chen, Y; Deng, C; Gu, Y; He, Y; Kong, T; Li, J; Shi, J; Sun, L; Yang, L; Zhang, W; Zhou, R | 1 |
| Beheshtirouy, S; Gharekhani, A; Khoshbaten, M; Rezaee, H; Shayanrad, S | 1 |
28 review(s) available for pioglitazone and d-alpha tocopherol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review.
Topics: Acetylcysteine; Adult; Alanine Transaminase; Aspartate Aminotransferases; Carnitine; Child; Dietary Supplements; Drug Synergism; Drug Therapy, Combination; Fatty Liver; Humans; Hypoglycemic Agents; Liver; Metformin; Pioglitazone; Probucol; Randomized Controlled Trials as Topic; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E | 2009 |
Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment.
Topics: Diabetes Mellitus, Type 2; Fatty Liver; Humans; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglitazone; Risk Factors; Thiazolidinediones; Treatment Outcome; Vitamin E; Weight Loss | 2011 |
Vitamin E and nonalcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Antioxidants; Diabetes Mellitus; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Liver; Humans; Meta-Analysis as Topic; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones; Treatment Outcome; Vitamin E | 2012 |
Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
Topics: Carcinoma, Hepatocellular; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones; Vitamin E; Weight Loss | 2013 |
State of the art: treatment of nonalcoholic steatohepatitis.
Topics: Antioxidants; Exercise; Humans; Hypoglycemic Agents; Life Style; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Thiazolidinediones; Vitamin E; Weight Loss | 2014 |
Nonalcoholic fatty liver disease: new treatments.
Topics: Antioxidants; Cardiovascular Diseases; Dyslipidemias; Humans; Hypoglycemic Agents; Insulin Resistance; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Risk Reduction Behavior; Thiazolidinediones; Vitamin E; Weight Loss | 2015 |
Nonalcoholic fatty liver disease: a systematic review.
Topics: Alanine Transaminase; Biomarkers; Biopsy; Diabetes Complications; Diet Therapy; Exercise; Fatty Liver; Humans; Liver; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Risk Factors; Thiazolidinediones; Vitamin E | 2015 |
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
Topics: Chenodeoxycholic Acid; Drug Therapy, Combination; Humans; Non-alcoholic Fatty Liver Disease; Pioglitazone; Publication Bias; Rosiglitazone; Thiazolidinediones; Vitamin E | 2015 |
Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
Topics: Bariatric Surgery; Diabetes Mellitus; Gastrointestinal Agents; Humans; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Thiazolidinediones; Transaminases; Treatment Outcome; United States; Vitamin E; Vitamins | 2015 |
Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Topics: Antioxidants; Bariatric Surgery; Exercise; Fatty Acids, Omega-6; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Thiazolidinediones; Vitamin E | 2016 |
The therapeutic landscape of non-alcoholic steatohepatitis.
Topics: Antioxidants; Chalcones; Chenodeoxycholic Acid; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pioglitazone; Propionates; Randomized Controlled Trials as Topic; Thiazolidinediones; Vitamin E; Weight Loss | 2017 |
Therapies in non-alcoholic steatohepatitis (NASH).
Topics: Carcinoma, Hepatocellular; Diet; Disease Progression; Exercise; Fibrosis; Humans; Hypoglycemic Agents; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Thiazolidinediones; Vitamin E | 2017 |
Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
Topics: Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; Inflammation; Liver Cirrhosis; Liver Neoplasms; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pioglitazone; Thiazolidinediones; Vitamin E | 2017 |
Review article: new treatments in non-alcoholic fatty liver disease.
Topics: Drug Design; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; MAP Kinase Kinase Kinase 5; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones; Vitamin E | 2017 |
Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.
Topics: Antioxidants; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Thiazolidinediones; Vitamin E | 2017 |
[Treatment of non-alcoholic fatty liver disease].
Topics: Bariatric Surgery; Chalcones; Chenodeoxycholic Acid; Critical Pathways; Humans; Hypoglycemic Agents; Life Style; Liraglutide; Non-alcoholic Fatty Liver Disease; Pioglitazone; Propionates; Risk Assessment; Vitamin E | 2018 |
Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
Topics: Bariatric Surgery; Chenodeoxycholic Acid; Diet; Exercise; Heart Diseases; Humans; Life Style; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Vitamin E | 2018 |
Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults.
Topics: Adult; Diet; Disease Progression; Drug Development; Humans; Life Style; Non-alcoholic Fatty Liver Disease; Pioglitazone; Vitamin E | 2019 |
Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients.
Topics: Biomarkers; Biopsy; Diagnostic Imaging; Diet; Disease Progression; Humans; Hypoglycemic Agents; Life Style; Liver Transplantation; Non-alcoholic Fatty Liver Disease; Pioglitazone; Vitamin E | 2019 |
Nonalcoholic Fatty Liver Disease and Obesity Treatment.
Topics: Bariatric Surgery; Body Weight; Diet; Exercise; Glucagon-Like Peptide 1; Humans; Inflammation; Insulin Resistance; Liver; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Prostatic Neoplasms; Vitamin E; Weight Loss | 2019 |
Diagnosis and management of non-alcoholic fatty liver disease.
Topics: Antioxidants; Diabetes Mellitus, Type 2; Disease Management; Elasticity Imaging Techniques; Exercise; Humans; Hypoglycemic Agents; Liver; Liver Cirrhosis; Magnetic Resonance Imaging; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Tomography, X-Ray Computed; Ultrasonography; Vitamin E; Weight Reduction Programs | 2019 |
A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH).
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Guidelines as Topic; Humans; Life Style; Non-alcoholic Fatty Liver Disease; Pioglitazone; Vitamin E | 2019 |
Position statement on the diagnosis and management of non-alcoholic fatty liver disease.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Chalcones; Chenodeoxycholic Acid; Diagnostic Imaging; Healthy Lifestyle; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Liver; Liver Transplantation; Mass Screening; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prevalence; Propionates; Thiazolidinediones; Vitamin E | 2019 |
Current and new pharmacotherapy options for non-alcoholic steatohepatitis.
Topics: Chenodeoxycholic Acid; Clinical Trials as Topic; Fibroblast Growth Factors; Glucagon-Like Peptides; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Vitamin E | 2020 |
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2021 |
Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.
Topics: Biopsy; Humans; Liver Cirrhosis; Network Meta-Analysis; Non-alcoholic Fatty Liver Disease; Pioglitazone; Vitamin E | 2021 |
Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled tria
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Necrosis; Network Meta-Analysis; Non-alcoholic Fatty Liver Disease; Pilot Projects; Pioglitazone; Randomized Controlled Trials as Topic; Vitamin E | 2023 |
11 trial(s) available for pioglitazone and d-alpha tocopherol
| Article | Year |
|---|---|
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
Topics: 3-Hydroxybutyric Acid; Alanine Transaminase; Antioxidants; Drug Therapy, Combination; Fatty Acids, Nonesterified; Fatty Liver; Female; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Logistic Models; Male; Middle Aged; Pilot Projects; Pioglitazone; Prospective Studies; Thiazolidinediones; Treatment Outcome; Vitamin E | 2004 |
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.
Topics: Antioxidants; Double-Blind Method; Fatty Liver; Humans; Hypoglycemic Agents; Pioglitazone; Research Design; Thiazolidinediones; Vitamin E | 2009 |
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Topics: Adult; Antioxidants; Chi-Square Distribution; Double-Blind Method; Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Intention to Treat Analysis; Liver; Male; Middle Aged; Pioglitazone; Thiazolidinediones; Transaminases; Vitamin E; Weight Gain | 2010 |
Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
Topics: Adipose Tissue; Adult; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Liver; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Reference Values; Thiazolidinediones; Time Factors; Treatment Outcome; Vitamin E | 2012 |
Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Antioxidants; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones; Vitamin E; Weight Loss | 2013 |
NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Humans; Lipoproteins, HDL; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Risk; Thiazolidinediones; Triglycerides; Vitamin E | 2015 |
Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.
Topics: Adult; Biomarkers; Biopsy; Dyslipidemias; E-Selectin; Female; Humans; Intercellular Adhesion Molecule-1; Lipoproteins; Macrophage Activation; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Particle Size; Pioglitazone; Remission Induction; Retrospective Studies; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vitamin E | 2019 |
Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Iran; Lipids; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Risk Reduction Behavior; Silymarin; Time Factors; Treatment Outcome; Vitamin E; Waist Circumference; Young Adult | 2019 |
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Adult; Biopsy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Inflammation; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Proof of Concept Study; Treatment Outcome; Vitamin E; Vitamins | 2019 |
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pioglitazone; Proteomics; Vitamin E | 2023 |
Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Humans; Hypoglycemic Agents; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Vitamin E | 2023 |
17 other study(ies) available for pioglitazone and d-alpha tocopherol
| Article | Year |
|---|---|
Troglitazone has a scavenging effect on reactive oxygen species.
Topics: Antioxidants; Chromans; Cytochrome c Group; Dimethyl Sulfoxide; Electron Spin Resonance Spectroscopy; Free Radical Scavengers; Humans; Hydrogen Peroxide; Iron; Molecular Structure; Neutrophils; Pioglitazone; Reactive Oxygen Species; Spin Labels; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Troglitazone; Vitamin E; Xanthine; Xanthine Oxidase; Xanthines | 1997 |
Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.
Topics: Adenosine Diphosphate; Blood Platelets; Blood Proteins; Chromans; Collagen; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Hypoglycemic Agents; In Vitro Techniques; Isoenzymes; Kinetics; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Phosphorylation; Pioglitazone; Platelet Aggregation; Platelet Aggregation Inhibitors; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-alpha; Thiazoles; Thiazolidinediones; Thrombin; Troglitazone; Vitamin E | 1998 |
Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat hearts.
Topics: Animals; Chromans; Dose-Response Relationship, Drug; Hemodynamics; Hypoglycemic Agents; Indomethacin; Isoxazoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Perfusion; Pioglitazone; Prostaglandins; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vitamin E | 2000 |
Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes.
Topics: alpha-Tocopherol; Animals; Cells, Cultured; Chromans; Gene Expression; Hypoglycemic Agents; Muscle, Smooth, Vascular; Pioglitazone; Promoter Regions, Genetic; Rats; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; Receptors, Thromboxane; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone | 2001 |
Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diet; Hypertension; Insulin; Kidney; Male; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase; Obesity; Oxidative Stress; Pioglitazone; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Sodium; Thiazolidinediones; Transcription Factors; Vitamin E | 2004 |
Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers?
Topics: 3-Hydroxybutyric Acid; Alanine Transaminase; Antioxidants; Drug Therapy, Combination; Fatty Acids, Nonesterified; Fatty Liver; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Thiazolidinediones; Vitamin E | 2004 |
Pioglitazone, a PPAR-gamma ligand inhibited the nicotinamide-streptozotocin induced sperm abnormalities in type-2 diabetic Wistar rats.
Topics: alpha-Tocopherol; Animals; Antioxidants; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Hypoglycemic Agents; Male; Niacinamide; Oxidative Stress; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Spermatozoa; Streptozocin; Thiazolidinediones | 2010 |
[Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis].
Topics: Fatty Liver; Humans; Hypoglycemic Agents; Liver Cirrhosis; Liver Neoplasms; Pioglitazone; Prognosis; Risk Factors; Thiazolidinediones; Vitamin E | 2012 |
Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis.
Topics: Combined Modality Therapy; Cost-Benefit Analysis; Fatty Liver; Humans; Hypoglycemic Agents; Life Style; Liver Cirrhosis; Markov Chains; Non-alcoholic Fatty Liver Disease; Pioglitazone; Quality-Adjusted Life Years; Severity of Illness Index; Thiazolidinediones; Vitamin E; Vitamins | 2012 |
Treatment of NASH: What Helps Beyond Weight Loss?
Topics: Alcohol Drinking; Comorbidity; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Humans; Hypoglycemic Agents; Liver Function Tests; Non-alcoholic Fatty Liver Disease; Patient Care Planning; Pioglitazone; Prognosis; Risk Assessment; Risk Factors; Vitamin E; Weight Loss | 2017 |
Effects of pioglitazone hydrochloride and vitamin E on meat quality, antioxidant status and fatty acid profiles in finishing pigs.
Topics: Adipose Tissue; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Antioxidants; Body Composition; Cooking; Diet; Dietary Supplements; Fatty Acids; Fatty Acids, Unsaturated; Female; Glutathione Peroxidase; Hypoglycemic Agents; Male; Muscle, Skeletal; Pioglitazone; Random Allocation; Red Meat; Superoxide Dismutase; Sus scrofa; Thiazolidinediones; Vitamin E | 2018 |
Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand.
Topics: Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Hypoglycemic Agents; Liver Cirrhosis; Liver Neoplasms; Markov Chains; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Quality-Adjusted Life Years; Thailand; Vitamin E; Weight Loss; Weight Reduction Programs | 2019 |
Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Topics: Adult; Biopsy; Chenodeoxycholic Acid; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Retrospective Studies; Treatment Outcome; Vitamin E; Vitamins | 2019 |
Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis.
Topics: Adult; Aspartate Aminotransferases; Biomarkers; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Severity of Illness Index; Vitamin E | 2021 |
Endogenous vitamin E metabolites mediate allosteric PPARγ activation with unprecedented co-regulatory interactions.
Topics: Allosteric Regulation; Animals; Benzopyrans; Binding Sites; Crystallography, X-Ray; Hep G2 Cells; Humans; Ligands; Molecular Dynamics Simulation; Pioglitazone; PPAR gamma; Protein Binding; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Transcriptome; Vitamin E | 2021 |
Platelet-neutrophil hybrid membrane-coated gelatin nanoparticles for enhanced targeting ability and intelligent release in the treatment of non-alcoholic steatohepatitis.
Topics: Animals; Gelatin; Liver; Nanoparticles; Neutrophils; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rats; Vitamin E | 2022 |
Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life.
Topics: Fibrosis; Humans; Ligands; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Patient Reported Outcome Measures; Pioglitazone; Quality of Life; Vitamin E | 2022 |